These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12188889)

  • 41. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
    Zucker S; Cao J; Chen WT
    Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted therapy: novel agents against cancer.
    Tongyoo A
    J Med Assoc Thai; 2010 Dec; 93 Suppl 7():S311-23. PubMed ID: 21294432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor cell metabolism: cancer's Achilles' heel.
    Kroemer G; Pouyssegur J
    Cancer Cell; 2008 Jun; 13(6):472-82. PubMed ID: 18538731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents.
    Chun YJ; Kim S
    Med Res Rev; 2003 Nov; 23(6):657-68. PubMed ID: 12939788
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?
    Dempke WCM; Uciechowski P; Fenchel K; Chevassut T
    Oncology; 2018; 95(5):257-269. PubMed ID: 29925063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic differences in drug disposition.
    May DG
    J Clin Pharmacol; 1994 Sep; 34(9):881-97. PubMed ID: 7983231
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug metabolism in carcinogenesis and cancer chemotherapy.
    Graham MA; Riley RJ; Kerr DJ
    Pharmacol Ther; 1991; 51(2):275-89. PubMed ID: 1784632
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carcinogen metabolism and individual susceptibility.
    Pelkonen O
    Scand J Work Environ Health; 1992; 18 Suppl 1():17-21. PubMed ID: 1411373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction of 2,4,4'-trichloro-2'-hydroxydiphenyl ether with microsomal cytochrome P450-dependent monooxygenases in rat liver.
    Hanioka N; Omae E; Nishimura T; Jinno H; Onodera S; Yoda R; Ando M
    Chemosphere; 1996 Jul; 33(2):265-76. PubMed ID: 8696774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
    Hyland R; Roe EG; Jones BC; Smith DA
    Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanism of inhibition of microsomal drug metabolism by imidazole.
    Hajek KK; Cook NI; Novak RF
    J Pharmacol Exp Ther; 1982 Oct; 223(1):97-104. PubMed ID: 7120133
    [No Abstract]   [Full Text] [Related]  

  • 53. Possible mechanisms of alteration in the capacities of carcinogen metabolizing enzymes during schistosomiasis and their role in bladder cancer induction.
    Badawi AF; Mostafa MH
    J Int Med Res; 1993; 21(6):281-305. PubMed ID: 8143885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents].
    Eskens FA; de Jonge MJ; Verweij J
    Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2208-13. PubMed ID: 11757242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Issues and progress with protein kinase inhibitors for cancer treatment.
    Dancey J; Sausville EA
    Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.
    Gradishar WJ
    Invest New Drugs; 1997; 15(1):49-59. PubMed ID: 9195289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic angiogenesis inhibitors in the treatment of cancer.
    Hidalgo M; Pierson AS; Holden SN; Bergen M; Eckhardt SG
    Adv Intern Med; 2001; 47():159-90. PubMed ID: 11795074
    [No Abstract]   [Full Text] [Related]  

  • 58. Cytochrome P450 expression in oesophageal cancer.
    Murray GI; Shaw D; Weaver RJ; McKay JA; Ewen SW; Melvin WT; Burke MD
    Gut; 1994 May; 35(5):599-603. PubMed ID: 8200549
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Targeted therapies and radiotherapy].
    Hennequin C; Giocanti N; Favaudon V
    Bull Cancer; 2005 Dec; 92(12):1085-92. PubMed ID: 16396755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacogenetics and human cancer.
    Nebert DW
    IARC Sci Publ; 1982; (39):365-80. PubMed ID: 7152614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.